ORGANON & CO.

Drug pipeline (62)

Asset	Stage	Revenue	Trials	Status
IMPLANON	approved	$230.0MQ2 2026	3	approved
NEXPLANON	approved	$230.0MQ2 2026	3	approved
ZETIA	approved	$96.0MQ2 2026	68	approved
FOLLISTIM AQ	approved	$59.0MQ2 2026	2	approved
NASONEX	approved	$58.0MQ2 2026	40	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (450)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00145470	phase3	completed	2005-06-02	2007-02-28	Organon and Co	12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
NCT00159744	phase3	completed	2004-11-30	2006-04-29	Organon and Co	3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
NCT00159796	phase3	completed	2004-12-14	2006-03-28	Organon and Co	3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
NCT00641771	phase1	completed	2004-05-01	2005-08-01	Organon and Co	4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)
NCT00159783	phase3	completed	2005-07-01	2007-04-01	Organon and Co	40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

FDA applications (66)

Application

Approved

Type

Applicant

Products

NDA 215272

2022-05-23

NDA

ORGANON LLC

NDA 215650

2021-12-07

NDA

ORGANON LLC

NDA 205641

2014-04-25

NDA

ORGANON LLC

NDA 200153

2013-05-03

NDA

ORGANON LLC A SUB OF ORGANON AND CO

NDA 022518

2010-06-22

NDA

ORGANON LLC